Gregory T. Went

Founder at Adamas Pharmaceuticals, Inc.

Gregory T. Went

Gregory T. Went

Founder at Adamas Pharmaceuticals, Inc.

Overview
Career Highlights

Neuromolecular Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc.
Tethys Bioscience, Inc.

RelSci Relationships

249

Number of Boards

6

Birthday

1964

Age

57

Contact Data
Trying to get in touch with Gregory T. Went? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Gregory T. Went likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Catalysis Foundation for Health, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Adamas Pharmaceuticals, Inc.

Relationship likelihood: Strong

Managing Director at GE Capital Equity, Inc.

Relationship likelihood: Strong

Managing Partner at Mohr Davidow Ventures

Relationship likelihood: Strong

Founder at BFLY Operations, Inc.

Relationship likelihood: Strong

Chief Medical Officer at SetPoint Medical Corp.

Relationship likelihood: Strong

Clinical Professor of Medicine at UCSF School of Medicine

Relationship likelihood: Strong

Senior Vice President & General Counsel at Angion Biomedica Corp.

Relationship likelihood: Strong

Chief Financial Officer & Chief Accounting Officer at Adamas Pharmaceuticals, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Sonitus Technologies, Inc.

Relationship likelihood: Strong

Paths to Gregory T. Went
Potential Connections via
Relationship Science
You
Gregory T. Went
Founder at Adamas Pharmaceuticals, Inc.
Education
Ph.D. in Chemical Engineering

University of California Berkeley National rankings: In a National Research Council analysis of 212 doctoral programs at American universities, 48 Berkeley programs place among the top 10 nationwide. Faculty awards and honors: There are 8 Nobel Laureates, 32 MacArthur Fellows, and 4 Pulitzer Prize winners among the current faculty. History of UC Berkeley: Historical highlights, arranged by topic, following the campus's development — from UC's founding in 1868 to a turn-of-the-century building boom, a research explosion in the 1930s, the Free Speech Movement of the '60s, and Berkeley's key role today in science and technology revolutions. Timeline of discoveries and contributions by UC Berkeley scholars. Traditions of Cal: Who was the Angel of Death? What's with the "Big C" up there in the hills — and why is it sometimes green? Who wears Oski's jolly bear head and size 54 yellow sweater? Tours and webcams: Check out what's happening on Sproul Plaza, the campus's true heart. See stunning live views of the Bay Area from the Lawrence Hall of Science's perch in the Berkeley hills. Chancellor and administration: Information on Chancellor Robert Birgeneau, Executive Vice Chancellor and Provost George W. Breslauer, and how the university is organized. Organizational charts are included. UC System overview and links: On the campuses, laboratories, and medical centers that comprise UC's public educational system, as well as UC's K-12 partnerships, economic impact, and agriculture and environmental resources.

B.S. in Chemical Engineering

Carnegie Mellon University challenges the curious and passionate to imagine and deliver work that matters. A private, global research university, Carnegie Mellon stands among the world's most renowned educational institutions, and sets its own course.With cutting-edge brain science, path-breaking performances, innovative start-ups, driverless cars, big data, big ambitions, Nobel and Turing prizes, hands-on learning, and a whole lot of robots, CMU doesn't imagine the future, they create it.

BS Chemical Engineering

Carnegie Mellon’s School of Design is one of the oldest and most respected programs in North America, with a rich history in Product (Industrial) Design, Communication (Graphic) Design, Interaction and Service Design. It is one of the only leading programs to offer design degrees at the undergraduate, graduate and doctoral levels within a multi-disciplinary, multi-cultural research university.

Career History
Founder
2004 - 2019

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Co-Founder
2002 - Prior

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

Co-Founder
1992 - 1999

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Boards & Committees
Chairman, Board of Directors
Prior - 2019

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Director
2006 - Prior

Angelica Therapeutics is a company offering fusion toxin therapeutic service.

Chairman & Chief Executive Officer
2002 - Prior
Political Donations
$2,300
2008

Former President of United States

Investments
Details Hidden

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

Details Hidden

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gregory T. Went. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gregory T. Went's profile does not indicate a business or promotional relationship of any kind between RelSci and Gregory T. Went.